Exchange: NASDAQ·Updated 04:54 PM EDT
ALZN logo

ALZN Alzamend Neuro Inc

$1.22
$0.03
(2.52%)
Today
Closed $1.22
$0.01
(0.82%)
After Hours
Reported EarningsSep 16
Mkt Cap$5.89M
Vol15,788.00

About ALZN

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.
46

Neutral Sentiment

How do you feel about ALZN?

ka1954
$ALZN what the fuck happened overnight? just dont get this fucking stock. it took 3 months to go up and then 1 day killed
2
hiwatt
$ALZN Over one later and no clinical trial started by Harvard after 10 years of research.---Lithium Depletion is an Early Hallmark: Brain lithium levels were high in cognitively healthy individuals, but severely depleted in those with Mild Cognitive Impairment (MCI) and early Alzheimer’s. Amyloid Plaque Sequestration: As toxic amyloid-beta proteins form, they act like a sponge—binding to and trapping free lithium in the brain. This deprives neurons, glia, and microglia of the essential trace lithium needed to maintain normal synaptic function and suppress neuroinflammation. Reversal of Cognitive Loss in Preclinical Models: When researchers administered an amyloid-evading lithium compound—specifically Lithium Orotate—at ultra-low micro-doses, it bypassed plaque trapping, reduced neuroinflammation, restored synaptic connections, and reversed memory loss in mice without any cellular toxicity.
1
hiwatt
$ALZN Looks like the sell side is drying up, opened $1.19 and moved to $1.36 on 700 shares. Still holding 52% institutional ownership.
hiwatt
$ALZN 2. But he was always bothered by a missing link in what came to be known as the amyloid hypothesis of Alz: Some people can have brains riddled with amyloid plaques and have relatively intact cognition, while others who have similar amounts of amyloid are severely impaired. The recent findings provide an explanation. By showing that amyloid binds to and neutralizes lithium and that aging individuals can vary in their baseline lithium levels, Yankner’s team may be starting to understand the imperfect correlation between amyloid and disease symptoms. It was a finding 10 years in the making. It required overcoming several technological hurdles, such as the ability to detect very low levels of a metal not previously thought to exist naturally in the body; the development of mouse models that could demonstrate the impact of a loss of lithium in the brain; and the creation of a new screening platform to test a series of lithium "COMPOUNDS" to find those that can evade lithium binding.
ka1954
$ALZN so these fuckers hvae to do manipulatoin in every fucking stock on my list, dont they?
ka1954
$ALZN come on man. is this stock for fucking real? 90k volume only and down 20%. fuck this shit

Advertisement|Remove ads.